Cargando…

Two Toxic Lipid Aldehydes, 4-hydroxy-2-hexenal (4-HHE) and 4-hydroxy-2-nonenal (4-HNE), Accumulate in Patients with Chronic Kidney Disease

Lipid aldehydes originating from the peroxidation of n-3 and n-6 polyunsaturated fatty acids are increased in hemodialysis (HD) patients, a process already known to promote oxidative stress. However, data are lacking for patients with chronic kidney disease (CKD) before the initiation of HD. We pros...

Descripción completa

Detalles Bibliográficos
Autores principales: Soulage, Christophe O., Pelletier, Caroline C., Florens, Nans, Lemoine, Sandrine, Dubourg, Laurence, Juillard, Laurent, Guebre-Egziabher, Fitsum
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551374/
https://www.ncbi.nlm.nih.gov/pubmed/32899405
http://dx.doi.org/10.3390/toxins12090567
_version_ 1783593169810620416
author Soulage, Christophe O.
Pelletier, Caroline C.
Florens, Nans
Lemoine, Sandrine
Dubourg, Laurence
Juillard, Laurent
Guebre-Egziabher, Fitsum
author_facet Soulage, Christophe O.
Pelletier, Caroline C.
Florens, Nans
Lemoine, Sandrine
Dubourg, Laurence
Juillard, Laurent
Guebre-Egziabher, Fitsum
author_sort Soulage, Christophe O.
collection PubMed
description Lipid aldehydes originating from the peroxidation of n-3 and n-6 polyunsaturated fatty acids are increased in hemodialysis (HD) patients, a process already known to promote oxidative stress. However, data are lacking for patients with chronic kidney disease (CKD) before the initiation of HD. We prospectively evaluated the changes of plasma concentrations of two major lipid aldehydes, 4-HHE and 4-HNE, according to the decrease of glomerular filtration rate (GFR) in 40 CKD and 13 non-CKD participants. GFR was measured by inulin or iohexol clearance. Thus, 4-hydroxy-2-nonenal (4-HNE) and 4-hydroxy-2-hexenal (4-HHE) were quantitated in plasma by gas chromatography coupled with mass spectrometry and their covalent adducts on proteins were quantified by immunoblotting. On the one hand, 4-HHE plasma concentration increased from CKD stage I–II to CKD stage IV–V compared to non-CKD patients (4.5-fold higher in CKD IV–V, p < 0.005). On the other hand, 4-HNE concentration only increased in CKD stage IV–V patients (6.2-fold, p < 0.005). The amount of covalent adducts of 4-HHE on plasma protein was 9.5-fold higher in CKD patients than in controls (p < 0.005), while no difference was observed for 4-HNE protein adducts. Plasma concentrations of 4-HNE and 4-HHE are increased in CKD IV–V patients before the initiation of hemodialysis.
format Online
Article
Text
id pubmed-7551374
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75513742020-10-14 Two Toxic Lipid Aldehydes, 4-hydroxy-2-hexenal (4-HHE) and 4-hydroxy-2-nonenal (4-HNE), Accumulate in Patients with Chronic Kidney Disease Soulage, Christophe O. Pelletier, Caroline C. Florens, Nans Lemoine, Sandrine Dubourg, Laurence Juillard, Laurent Guebre-Egziabher, Fitsum Toxins (Basel) Article Lipid aldehydes originating from the peroxidation of n-3 and n-6 polyunsaturated fatty acids are increased in hemodialysis (HD) patients, a process already known to promote oxidative stress. However, data are lacking for patients with chronic kidney disease (CKD) before the initiation of HD. We prospectively evaluated the changes of plasma concentrations of two major lipid aldehydes, 4-HHE and 4-HNE, according to the decrease of glomerular filtration rate (GFR) in 40 CKD and 13 non-CKD participants. GFR was measured by inulin or iohexol clearance. Thus, 4-hydroxy-2-nonenal (4-HNE) and 4-hydroxy-2-hexenal (4-HHE) were quantitated in plasma by gas chromatography coupled with mass spectrometry and their covalent adducts on proteins were quantified by immunoblotting. On the one hand, 4-HHE plasma concentration increased from CKD stage I–II to CKD stage IV–V compared to non-CKD patients (4.5-fold higher in CKD IV–V, p < 0.005). On the other hand, 4-HNE concentration only increased in CKD stage IV–V patients (6.2-fold, p < 0.005). The amount of covalent adducts of 4-HHE on plasma protein was 9.5-fold higher in CKD patients than in controls (p < 0.005), while no difference was observed for 4-HNE protein adducts. Plasma concentrations of 4-HNE and 4-HHE are increased in CKD IV–V patients before the initiation of hemodialysis. MDPI 2020-09-03 /pmc/articles/PMC7551374/ /pubmed/32899405 http://dx.doi.org/10.3390/toxins12090567 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Soulage, Christophe O.
Pelletier, Caroline C.
Florens, Nans
Lemoine, Sandrine
Dubourg, Laurence
Juillard, Laurent
Guebre-Egziabher, Fitsum
Two Toxic Lipid Aldehydes, 4-hydroxy-2-hexenal (4-HHE) and 4-hydroxy-2-nonenal (4-HNE), Accumulate in Patients with Chronic Kidney Disease
title Two Toxic Lipid Aldehydes, 4-hydroxy-2-hexenal (4-HHE) and 4-hydroxy-2-nonenal (4-HNE), Accumulate in Patients with Chronic Kidney Disease
title_full Two Toxic Lipid Aldehydes, 4-hydroxy-2-hexenal (4-HHE) and 4-hydroxy-2-nonenal (4-HNE), Accumulate in Patients with Chronic Kidney Disease
title_fullStr Two Toxic Lipid Aldehydes, 4-hydroxy-2-hexenal (4-HHE) and 4-hydroxy-2-nonenal (4-HNE), Accumulate in Patients with Chronic Kidney Disease
title_full_unstemmed Two Toxic Lipid Aldehydes, 4-hydroxy-2-hexenal (4-HHE) and 4-hydroxy-2-nonenal (4-HNE), Accumulate in Patients with Chronic Kidney Disease
title_short Two Toxic Lipid Aldehydes, 4-hydroxy-2-hexenal (4-HHE) and 4-hydroxy-2-nonenal (4-HNE), Accumulate in Patients with Chronic Kidney Disease
title_sort two toxic lipid aldehydes, 4-hydroxy-2-hexenal (4-hhe) and 4-hydroxy-2-nonenal (4-hne), accumulate in patients with chronic kidney disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551374/
https://www.ncbi.nlm.nih.gov/pubmed/32899405
http://dx.doi.org/10.3390/toxins12090567
work_keys_str_mv AT soulagechristopheo twotoxiclipidaldehydes4hydroxy2hexenal4hheand4hydroxy2nonenal4hneaccumulateinpatientswithchronickidneydisease
AT pelletiercarolinec twotoxiclipidaldehydes4hydroxy2hexenal4hheand4hydroxy2nonenal4hneaccumulateinpatientswithchronickidneydisease
AT florensnans twotoxiclipidaldehydes4hydroxy2hexenal4hheand4hydroxy2nonenal4hneaccumulateinpatientswithchronickidneydisease
AT lemoinesandrine twotoxiclipidaldehydes4hydroxy2hexenal4hheand4hydroxy2nonenal4hneaccumulateinpatientswithchronickidneydisease
AT dubourglaurence twotoxiclipidaldehydes4hydroxy2hexenal4hheand4hydroxy2nonenal4hneaccumulateinpatientswithchronickidneydisease
AT juillardlaurent twotoxiclipidaldehydes4hydroxy2hexenal4hheand4hydroxy2nonenal4hneaccumulateinpatientswithchronickidneydisease
AT guebreegziabherfitsum twotoxiclipidaldehydes4hydroxy2hexenal4hheand4hydroxy2nonenal4hneaccumulateinpatientswithchronickidneydisease